Check out our latest video!🌟
Discover how our team triumphed over challenges like COVID-19 and sensor shortages to recruit over 2,382 patients for one of the largest clinical validation studies ever. Plus, catch some fun behind-the-scenes moments! 🎥✨
https://t.co/lrjMRkvmoE
Sheffield produced seven first authored posters and a co authored talk at @ECTRIMS this year covering @Mobilise_D, aHSCT and remote ischaemic conditioning in multiple sclerosis. More to come in the next few months! @SheffieldBRC@neuroshef@ee_buckley
☝️ Sequential lymph node biopsies after #CD19-CAR T-cell therapy:
🔹CD19+, CD20+ cells, follicular DC completely depleted after CD19-CAR T-cells, but not after #rituximab
🔹Follicular structures disrupted
🔹Plasma cells, T cells and macrophages unchanged
https://t.co/ebHzNMkThH
#CART in Immune-Mediated Neurological Diseases, including MS, NMO, MG, CIDP,
stiff person syndrome, might be an effective option for patients, avoiding the need for long-term immunosuppressant medications.
A new manuscript on behalf of @TheEBMT ADWP.
https://t.co/HejUBhAcdc
New research shows the number of people estimated to be living with multiple sclerosis (MS) in the UK has increased to more than 150,000.
The previous figure, based on data from 2019, was more than 130,000.
Read more here: https://t.co/qaLtrIYDx6
Congratulations to the @Mobilise_D team in #Sheffield! 👏👏👏
Over 26 years' worth of real-world mobility data collected from people with #MultipleSclerosis to improve future clinical trials and patient care 🚶♀️
Well done team - a fantastic achievement!
https://t.co/I958KMYnRH